Understanding gout symptoms and treatment starts with a fact that surprises most people: the blood test everyone associates with the condition can look perfectly normal in the middle of an attack. Gout is the most common form of inflammatory arthritis in American adults, and one of the most misread.
In this article you will learn why serum uric acid can mislead during a flare, which test actually confirms the diagnosis, how flare relief differs from long-term urate-lowering therapy, what target number your clinician aims for, which labs get monitored once you start medication, and how much diet genuinely contributes. Gout is one of the few forms of arthritis that can be brought under lasting control when the numbers are read correctly.
What gout is and why it flares
Gout is caused by monosodium urate crystals that build up inside joints. Uric acid is the waste product your body makes when it breaks down purines, building blocks found in your own cells and in many foods, and about two thirds of it leaves through the kidneys.
Urate stays dissolved in blood only up to roughly 6.8 mg/dL. Above that ceiling it can crystallize, slowly and silently, in the cooler joints of the feet, ankles and hands, and those deposits can sit there for years without causing pain. A flare begins when crystals are shed into the joint space and the immune system treats them as an intruder, releasing inflammatory signals that produce heat, redness and severe pain within hours.
Who is most likely to develop gout
Risk rises with anything that raises urate or slows its clearance: male sex, menopause in women, excess body weight, high blood pressure, reduced kidney function, certain diuretics and low-dose aspirin, heavy beer or spirits intake, drinks sweetened with fructose, and a family history. Genetics matter more than most people expect, since variation in the kidney transporters that handle urate explains much of the difference between individuals.
People with recurrent stones often review kidney stone types and their causes, because uric acid can crystallize in the urinary tract as well as in joints.
Gout symptoms: what a flare actually feels like
Both gout symptoms and treatment decisions begin with recognizing the pattern. A first flare is dramatic and involves a single joint, in roughly half of cases the base of the big toe, a presentation clinicians call podagra. Pain often begins at night, peaks within 12 to 24 hours, and reaches an intensity that makes the weight of a bedsheet intolerable. The joint looks red, feels hot and swells. Left untreated, most first flares resolve within one to two weeks, and that spontaneous recovery is what lulls people into inaction.
How the pattern changes over time
Later flares involve more joints, last longer and recur more often: ankles, midfoot, knees, wrists, fingers and the elbow bursa. After years of uncontrolled urate, chalky deposits called tophi can appear under the skin of fingers, toes, elbows or ear cartilage, where they erode bone and permanently damage joints.
The quiet period between flares
Between attacks you feel fine. This intercritical period is misleading: the crystals are still there, low-grade inflammation continues even when nothing hurts, and the urate problem has not gone anywhere, so long-term treatment decisions are not made on how you feel today. One warning: a hot, swollen joint with fever can also be a joint infection, a medical emergency that a history of gout does not exclude.
Why a normal uric acid level does not rule out gout
This is the single most useful thing to know about gout lab testing. Serum uric acid frequently falls during an acute attack, sometimes into the normal range or below it, because urate is pulled out of the blood into crystals and inflamed tissue while the inflammatory response increases urate excretion by the kidneys. A substantial minority of people measured during a flare have a level under 6 mg/dL.
Mayo Clinic makes the point in both directions: a high level does not confirm gout, and some people with genuine gout symptoms do not have a high level during an attack. Asymptomatic hyperuricemia is common, and most people who have it never develop gout.
What to do instead
The practical fix is timing. A urate measured two to four weeks after the flare has settled gives a far more honest baseline, and that is the number used to guide long-term therapy. To interpret a value on your own report, review what a serum uric acid test measures and how laboratories set reference ranges, which are statistical rather than therapeutic.
Some clinicians also order a 24-hour collection to see whether you underexcrete urate or overproduce it, which can influence the choice of medication. That question is answered by measuring uric acid in a urine sample.
How doctors confirm gout
The definitive test is not a blood test. It is the identification of monosodium urate crystals in fluid drawn from the affected joint or from a tophus. A clinician withdraws a small amount of fluid with a needle, and a laboratory examines it under a polarized light microscope, where urate crystals appear as needles with a characteristic color pattern. The same sample is cultured, which rules out infection.
Imaging fills the gap when aspiration is impractical: ultrasound can show a bright line of urate coating the cartilage, and dual-energy CT color-codes deposits too small to feel. Neither replaces crystal identification.
Inflammatory markers rise during a flare but say nothing specific about the cause; readers comparing an elevated value with their symptoms often check what a C-reactive protein result indicates.
What gout gets confused with
Several conditions mimic a flare: calcium pyrophosphate deposition disease, sometimes called pseudogout, which produces different crystals; joint infection; cellulitis; and other inflammatory arthritis. Anyone with symmetrical small-joint swelling and morning stiffness should read about rheumatoid arthritis and its antibody tests, while people with gradual, activity-related pain may recognize the wear-related pattern of osteoarthritis.
| Test | What it shows | What it cannot do |
|---|---|---|
| Serum uric acid | Your long-term urate burden and your response to treatment | Confirm or exclude gout, especially during a flare |
| Joint fluid analysis | Urate crystals under polarized light; also detects infection | Be performed easily on every joint, and it needs a skilled reader |
| Ultrasound | Urate coating cartilage and early deposits | Distinguish reliably in very early disease |
| Dual-energy CT | Mapped urate deposits, including hidden ones | Rule out infection, and access is limited |
| Kidney and liver panels | Baseline safety before and during medication | Diagnose gout on their own |
Treating a flare versus treating the disease
This distinction causes more avoidable suffering than any other part of gout symptoms and treatment. Flare medication and urate-lowering medication do different jobs on different timescales, and they are not interchangeable.
Flare treatment is anti-inflammatory and short: nonsteroidal anti-inflammatory drugs, colchicine, which works best when started within the first 24 hours, and corticosteroids taken by mouth or injected into the joint. Interleukin-1 blockers are a specialist option for resistant attacks. None of these drugs lower urate or prevent the next flare.
Urate-lowering therapy is preventive and long term. Allopurinol is the usual first choice, with febuxostat as an alternative, uricosurics such as probenecid in selected cases, and an intravenous enzyme therapy for severe tophaceous disease. These drugs dissolve the crystal stockpile over months to years.
The three mistakes worth avoiding
- Taking allopurinol like a painkiller, only when a joint hurts. It does nothing for the pain in front of you and needs continuous use.
- Stopping urate-lowering therapy the moment a flare starts. Current practice is to continue it and treat the flare alongside.
- Abandoning treatment because flares still happen. Flares are common in the first six months, which is why a low-dose anti-inflammatory is usually prescribed during that window.
| Aspect | Flare treatment | Urate-lowering therapy |
|---|---|---|
| Goal | Stop pain and inflammation now | Dissolve crystals and prevent future flares |
| Typical agents | Colchicine, anti-inflammatories, corticosteroids | Allopurinol, febuxostat, uricosurics |
| Duration | Days | Years, often lifelong |
| Guided by | Symptoms | A serum urate target |
| Effect on uric acid | None | Substantial and sustained |
Treat-to-target: the urate number that guides therapy
Modern gout care is not dose-and-hope. It follows a treat-to-target approach: the dose of urate-lowering medication is raised step by step, with repeat blood tests, until serum urate reaches an agreed target and stays there. The target commonly used in the United States is below 6 mg/dL, under the level at which urate crystallizes; when tophi are present many clinicians aim lower, often below 5 mg/dL, because deposits dissolve faster the further the level falls. Professional guidance is set out in the American College of Rheumatology gout guideline.
Two consequences follow.
- Urate is rechecked every few weeks during dose adjustment, then once or twice a year when stable. A single normal reading early on does not mean the dose is right.
- Crystals dissolve slowly, so flares can continue for months while the number falls. That is expected rather than a sign of failure.
The most common reason treatment appears not to work is that the dose was never raised far enough. Starting allopurinol at 100 mg and never revisiting it leaves many people permanently above the crystallization threshold, with gout symptoms and treatment drifting out of step.
Monitoring your labs on urate-lowering medication
Urate-lowering drugs are generally well tolerated, but they are monitored, and knowing what is being watched makes the follow-up appointments make sense.
Kidney function
Kidney function sets both the starting dose and the pace of titration, and reduced function is common in gout. Baseline and periodic testing usually includes a serum creatinine measurement together with an estimated glomerular filtration rate. People whose results stay abnormal over months should understand the stages of chronic kidney disease, since gout and kidney disease each worsen the other.
Liver enzymes and blood counts
Both allopurinol and febuxostat can occasionally irritate the liver, so clinicians check liver enzymes before starting and periodically afterwards. To interpret those two values, look up what an ALT liver enzyme result means and the normal range for an AST test. A blood count is often added, because rare marrow effects have been reported.
The HLA-B*58:01 consideration
A small proportion of people carry a genetic variant called HLA-B*58:01 that markedly increases the risk of a severe allergic reaction to allopurinol involving the skin, liver and kidneys. It is far more frequent in people of Han Chinese, Korean, Thai and other Southeast Asian ancestry, and in African American populations, which is why US rheumatology guidance recommends testing for it before starting allopurinol in those groups. Starting low and increasing gradually lowers the risk for everyone. Whatever your background, a spreading rash, fever or feeling unwell in the first weeks on allopurinol is a reason to stop the drug and seek advice the same day.
Febuxostat and the heart
Febuxostat carries a US boxed warning about cardiovascular death in people with established heart disease, which is why it is usually reserved for those who cannot take or do not respond to allopurinol. That decision depends on your own cardiovascular history.
Diet, weight, and when to see a doctor
Diet deserves an honest weight rather than a starring role. Dietary change typically moves serum urate by a modest amount, often around 1 mg/dL or less, while an adequately dosed urate-lowering drug moves it several times further. For someone whose baseline is 9 mg/dL, diet alone will not close the gap.
That does not make it pointless. The changes with the best evidence are cutting beer and spirits, cutting drinks sweetened with high-fructose corn syrup, moderating organ meats and certain shellfish, and losing excess weight gradually. Two myths deserve retiring: purine-rich vegetables such as spinach, peas and mushrooms have not been shown to trigger flares, and low-fat dairy appears mildly protective. Metabolic conditions cluster around gout, so a flare is a good moment to review a fasting triglyceride result, which is often raised alongside high urate.
When to see a doctor
- Your first episode of a hot, swollen, intensely painful joint, so the diagnosis is confirmed rather than assumed.
- Joint pain with fever, chills or a spreading red area, which needs urgent assessment to exclude infection.
- Two or more flares in a year, any tophus, kidney stones, or joint damage on imaging: standard reasons to start long-term therapy.
- A flare that has not improved after 48 hours of treatment, or one affecting an artificial joint.
- Any rash, fever or unusual fatigue in the first weeks on a new urate-lowering drug.
Latest scientific advances
Research over the past three years has strengthened the case for measuring rather than guessing when gout symptoms and treatment are matched up. Here is what the most relevant recent work found, in plain terms.
Reaching the urate target may help more than the joints
A large study published in 2026 followed more than 100,000 people with gout newly prescribed urate-lowering treatment. Those who reached a serum urate below 6 mg/dL within the first year had slightly better survival free of major heart events over the next five years. What this means for you: hitting the target may matter for the heart, not only for pain. This was an observational study, meaning it followed people receiving usual care rather than assigning treatment, so it shows an association and not proof of cause.
Reduced kidney function does not rule out treatment
A planned analysis of a randomized trial looked at participants with moderately reduced kidney function. Allopurinol and febuxostat, each titrated upward until the urate target was reached, worked similarly well and were similarly tolerated. What this means for you: borderline kidney numbers call for careful dosing and monitoring, not for going without effective therapy.
Crystal identification depends on the reader
An analysis of ten years of external quality assessment data, published in 2026, found that a meaningful proportion of laboratories misidentified crystals in joint fluid samples sent to them. Quality assessment here means anonymized samples go to many labs so their answers can be compared. What this means for you: the definitive test is excellent in experienced hands, and if a result contradicts a typical clinical picture, it is fair to ask whether the sample should be reviewed again.
Faster crystal identification is being tested
A 2025 study combined Raman spectroscopy, a technique that identifies materials by how they scatter light, with machine learning to spot urate and calcium crystals in joint fluid in an outpatient clinic. The automated readings agreed closely with expert analysis. What this means for you: same-visit crystal confirmation may become more widely available, though this is early work in a few centers.
Diet and supplements: modest and inconsistent
A 2025 systematic review pooled 27 randomized trials of dietary patterns and supplements, including cherry products, omega-3 fats and vitamin C. The findings were mixed, with modest benefits at best. Separately, a randomized trial of an intensive low-energy diet in people with gout and obesity produced roughly twice the weight loss of the comparison diet, yet did not clearly reduce serum urate or joint pain over 16 weeks. What this means for you: eating well and losing excess weight are worth doing, but they complement urate-lowering therapy rather than replace it once flares are recurring.
Glossary
| Term | Definition |
|---|---|
| Hyperuricemia | A serum uric acid level above the point at which urate can crystallize, usually taken as about 6.8 mg/dL. Many people with it never develop gout. |
| Monosodium urate crystals | The needle-shaped crystals that form from excess urate and trigger gout flares when the immune system reacts to them. |
| Purines | Natural compounds found in body cells and in some foods. Breaking them down produces uric acid. |
| Podagra | A gout flare at the base of the big toe, the classic first presentation of the disease. |
| Arthrocentesis | Joint aspiration: drawing fluid from a joint with a needle so it can be examined and cultured. |
| Polarized light microscopy | A microscope technique that makes urate crystals show a distinctive color pattern, allowing them to be told apart from other crystals. |
| Tophus | A visible lump of accumulated urate crystals under the skin or near a joint, seen after years of uncontrolled gout. The plural is tophi. |
| Urate-lowering therapy | Long-term medication such as allopurinol or febuxostat that reduces serum urate so existing crystals dissolve and new ones stop forming. |
| Treat-to-target | A strategy in which medication doses are adjusted using repeat blood tests until an agreed serum urate level is reached and maintained. |
| Dual-energy CT | A scan that uses two X-ray energies to identify and color-code urate deposits in and around joints. |
Frequently asked questions
What triggers a gout attack?
Flares are usually set off by a sudden change in urate levels rather than by a single food. Common triggers include a heavy drinking session, dehydration, a crash diet or fasting, surgery, an acute illness, an injury to the joint, and starting or stopping certain medicines, including diuretics and urate-lowering drugs themselves. Cold joints and long periods of immobility can also contribute, which is partly why flares so often begin at night. Identifying your own pattern helps, but trigger avoidance alone rarely prevents recurrent gout if the underlying urate level stays high.
How can I ease gout pain during the night?
The most effective step is starting the anti-inflammatory treatment your clinician has prescribed as early in the attack as possible, ideally within the first day. Resting and elevating the joint, applying an ice pack wrapped in cloth for short periods, keeping bedding off the joint with a cradle or a rolled towel, and drinking water all help you get through the night. Avoid aspirin at low doses, which can raise urate. If pain is severe, if you have a fever, or if this is your first attack, seek medical advice rather than managing it alone.
Can gout be cured permanently?
Gout cannot be cured in the sense of being erased, but it can be put into lasting remission. When serum urate is kept below the crystallization threshold for long enough, existing deposits dissolve, tophi shrink and flares stop. Many people on well-dosed urate-lowering therapy go years without an attack. The tendency to accumulate urate remains, which is why stopping treatment usually leads to a slow return of crystals and, eventually, of flares.
What foods should I avoid with gout?
The changes with the strongest support are reducing beer and spirits, sugar-sweetened drinks containing high-fructose corn syrup, organ meats such as liver and kidney, and large servings of certain shellfish and red meat. Purine-rich vegetables have not been shown to trigger flares, and low-fat dairy appears mildly protective. Expect a modest effect: dietary change typically shifts urate by a small amount, which helps but rarely reaches a treatment target on its own.
Do urate crystals ever go away?
Yes, but slowly and only through chemistry rather than through anything mechanical. When blood urate is held below the saturation point, crystals gradually dissolve back into the bloodstream and are excreted. Imaging studies show deposits shrinking over months to years, faster at lower urate levels. There is no way to flush, massage or scrape crystals out of a joint, and no supplement has been shown to dissolve them.
Why does gout so often start in the big toe?
Urate crystallizes more readily at lower temperatures, and the big toe is one of the coolest joints in the body, farthest from the core. It also bears repeated mechanical load and has a relatively poor blood supply at the joint surface. Together these conditions favor crystal formation and shedding, which is why podagra is the classic first flare. The same physics explains why the ankles, midfoot, fingers and ear cartilage are also frequent sites.
Sources
- Mayo Clinic — Gout: diagnosis and treatment, 2025 — Mayo Clinic gout diagnosis and treatment
- Cleveland Clinic — Gout: symptoms, causes and treatment, 2025 — Cleveland Clinic gout overview
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH) — Gout, 2025 — NIAMS health topic on gout
- Cipolletta E, Zverkova Sandstrom T, Rozza D, et al. — Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with gout — JAMA Internal Medicine, 2026 — doi.org/10.1001/jamainternmed.2025.7453
- Helget LN, Davis-Karim A, O’Dell JR, et al. — Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP Gout trial — American Journal of Kidney Diseases, 2024 — doi.org/10.1053/j.ajkd.2024.04.017
- Gough R, Spies M, Badrick T — An analysis of 10 years of synovial fluid crystal external quality assurance data — Pathology, 2026 — doi.org/10.1016/j.pathol.2025.11.013
- Niessink T, Jansen TL, Coumans FAW, et al. — An objective diagnosis of gout and calcium pyrophosphate deposition disease with machine learning of Raman spectra acquired in a point-of-care setting — Rheumatology (Oxford), 2025 — doi.org/10.1093/rheumatology/keae472
- Pardali EC, Gkouvi A, Nasiou K, et al. — Effect of diet and dietary supplements on gout-related outcomes: a systematic review of randomised controlled trials — Mediterranean Journal of Rheumatology, 2025 — doi.org/10.31138/mjr.010725.era
- Christensen R, Zobbe K, Nielsen SM, et al. — Weight loss for patients with gout and concomitant obesity: a proof-of-concept randomized trial — Arthritis and Rheumatology, 2024 — doi.org/10.1002/art.42790
- McCarty KL, Gaffo AL, Diaz-Torne C, et al. — Gout therapy updated — Therapeutic Advances in Musculoskeletal Disease, 2025 — doi.org/10.1177/1759720X251384584
Further reading
- Readers reviewing a routine panel often start with a complete blood count and its components.
- People managing several risk factors at once frequently consult a plain-language guide to diabetes.
- Anyone reviewing a lipid report may want an explanation of high cholesterol.
- Those tracking kidney health can examine the albumin to creatinine ratio.
- Anyone comparing joint conditions can read an overview of the main arthritis types.
Understand your lab results with BloodSense
Gout is a condition where the numbers on your report do most of the talking, yet a uric acid value on its own rarely tells the whole story. BloodSense reads your results in context, connecting uric acid with kidney markers such as creatinine and estimated filtration rate, liver enzymes and inflammation markers, and explains in plain language what each value suggests and what it does not. It helps you understand your results and prepare better questions for your appointment; it does not diagnose and does not replace your doctor.
